|
GENERIC
|
Levobunolol HCI ophthalmic solution, USP 0.25%, 0.5%
|
|
INDICATIONS
|
Reduces intraocular pressure (IOP)
|
|
MECHANISM OF ACTION
|
Non-selective beta adrenergic receptor blocker
|
|
MICROBIOLOGY
|
The predominant mechanism of ocular hypotensive action of topical beta-adrenergic blocking agents is likely due to a reduction in aqueous humor production
|
|
CONTRAINDICATIONS & WARNINGS
|
Patients with bronchial asthma, or with a history of bronchial asthma, or severe chronic obstructive pulmonary disease, sinus bradycardia; second and third degree atrioventricular block; overt cardiac failure, cardiogenic shock; or hypersensitivity to any component of these products.
|
|
PEDIATRIC USE
|
Safety and effectiveness in pediatric patients have not been established.
|
|
PREGNANCY
|
Pregnancy category C | There are no adequate and well-controlled studies in pregnant women. BETAGAN® ophthalmic solution should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus
|
